Company / SG&A Expense
ROCKET PHARMACEUTICALS, INC. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$102.0M
FY2025
5-year range
$18.2M / $102.0M
FY2021-FY2025
Trend
+73.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 5 consecutive years, from $18M in FY2020 to $102M in FY2025.
Based on SEC 10-K filings.
$102M in FY2025 with a 5-year CAGR of +41.6%.
Increased from $42M to $102M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +52.3%
- 5-Year CAGR
- +41.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- ROCKET PHARMACEUTICALS, INC.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +41.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 73.5% year-over-year.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $102.0M | +73.5% |
| FY2024 | $58.8M | +40.7% |
| FY2023 | $41.8M | +44.7% |
| FY2022 | $28.9M | +58.2% |
| FY2021 | $18.2M | +2.0% |
| FY2020 | $17.9M | +0.0% |
| FY2019 | $17.9M | +1032.0% |
| FY2018 | $1.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026